NCT01401322View on ClinicalTrials.gov

Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

PHASE2TerminatedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

May 31, 2012

Conditions

LeukemiaRelapsed Adult Acute Lymphocytic Leukemia

Interventions

DRUG

Lenalidomide

50 mg; po

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

Stanford University

OTHER